• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Mylan Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYL

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Mylan in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for MYL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Mylan. This rating has held steady since October 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/28/2020Wells Fargo & CompanyLower TargetEqual Weight$17.00 ➝ $16.00Medium
9/8/2020Raymond JamesReiterated RatingBuyHigh
8/11/2020UBS GroupBoost TargetNeutral$17.00 ➝ $18.00Medium
5/13/2020UBS GroupBoost TargetNeutral$16.00 ➝ $17.00High
5/12/2020Royal Bank of CanadaReiterated RatingBuy$26.00High
4/30/2020Wells Fargo & CompanyLower TargetEqual Weight$23.00 ➝ $18.00Low
4/15/2020Piper SandlerLower TargetNeutral$23.00 ➝ $17.00Low
4/2/2020Morgan StanleyLower TargetEqual Weight$23.00 ➝ $18.00High
3/27/2020Royal Bank of CanadaLower TargetOutperform$27.00 ➝ $26.00Low
2/5/2020SunTrust BanksReiterated RatingBuy$27.00Medium
1/9/2020Piper SandlerInitiated CoverageNeutral$21.00Medium
1/6/2020Royal Bank of CanadaBoost TargetOutperform$25.00 ➝ $27.00High
12/16/2019Evercore ISIReiterated RatingBuyMedium
11/27/2019CfraUpgradeHoldLow
11/7/2019Morgan StanleyDowngradeOverweight ➝ Equal$25.00 ➝ $18.00Low
11/5/2019CfraDowngradeHold ➝ SellHigh
9/12/2019SunTrust BanksBoost TargetBuy$25.00 ➝ $27.00Low
8/9/2019Evercore ISIReiterated RatingBuyN/A
7/31/2019CitigroupSet TargetBuy$26.00Low
7/31/2019Credit Suisse GroupReiterated RatingBuy$34.50Low
7/30/2019MizuhoBoost TargetNeutral$25.00 ➝ $27.00Low
7/30/2019Morgan StanleyReiterated RatingOverweight$22.00 ➝ $25.00Low
7/19/2019Wolfe ResearchInitiated CoverageOutperform ➝ Outperform$27.00Low
7/15/2019Morgan StanleySet TargetBuy$22.00Low
6/12/2019Cantor FitzgeraldLower TargetNeutral$31.00 ➝ $18.00Low
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$26.00Medium
5/28/2019UBS GroupLower TargetNeutral$23.00Low
5/14/2019MizuhoReiterated RatingHoldMedium
5/8/2019Morgan StanleySet TargetBuy$32.00Medium
5/8/2019Raymond JamesSet TargetBuy$31.00Medium
5/8/2019BMO Capital MarketsSet TargetBuy$36.00Medium
5/8/2019Royal Bank of CanadaLower TargetOutperform$26.00Low
5/7/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$33.00 ➝ $22.00Low
4/1/2019Cantor FitzgeraldReiterated RatingHold$41.00High
3/27/2019ArgusLower TargetBuy$32.00Medium
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$35.00Low
3/7/2019UBS GroupReiterated RatingNeutral$31.00Low
3/6/2019Credit Suisse GroupReiterated RatingBuy$37.00Low
3/6/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$35.00Medium
2/27/2019Wells Fargo & CompanyLower TargetOutperform$40.00 ➝ $33.00High
2/27/2019BTIG ResearchLower TargetBuy$35.00High
2/27/2019BMO Capital MarketsBoost TargetOutperform$40.00High
2/27/2019Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$33.00High
1/31/2019MizuhoReiterated RatingNeutralHigh
1/23/2019UBS GroupDowngradeBuy ➝ Neutral$54.00 ➝ $32.00Medium
11/20/2018Cantor FitzgeraldReiterated RatingHold$41.00Low
11/15/2018ArgusUpgradeHold ➝ Buy$42.00Medium
11/6/2018JPMorgan Chase & Co.Set TargetBuy$45.00Low
11/6/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ Buy$40.00High
11/6/2018Royal Bank of CanadaLower TargetOutperform ➝ Buy$51.00 ➝ $50.00High
11/6/2018Morgan StanleyBoost TargetEqual Weight ➝ Hold$36.00 ➝ $39.00High
11/6/2018CitigroupLower TargetBuy ➝ Buy$48.00 ➝ $44.00High
11/6/2018CowenSet TargetHold$31.00High
11/6/2018Bank of AmericaUpgradeNeutral ➝ Buy$44.00 ➝ $42.00High
11/5/2018Cantor FitzgeraldReiterated RatingHold$41.00High
10/9/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$46.00 ➝ $36.00Low
10/5/2018MizuhoDowngradeBuy ➝ NeutralLow
8/24/2018Evercore ISIUpgradeIn-Line ➝ OutperformLow
8/15/2018Wells Fargo & CompanyReiterated RatingHoldLow
8/13/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$53.00Low
8/9/2018CitigroupLower TargetBuy ➝ Buy$50.00 ➝ $48.00High
8/9/2018SVB LeerinkLower TargetOutperform$53.00 ➝ $47.00High
8/9/2018Raymond JamesDowngradeStrong-Buy ➝ OutperformHigh
8/9/2018CowenReiterated RatingHold$31.00High
8/8/2018Cantor FitzgeraldReiterated RatingHold$41.00High
8/8/2018Wells Fargo & CompanySet TargetHold$41.00High
8/8/2018MizuhoReiterated RatingBuy$54.00High
8/2/2018Wells Fargo & CompanyReiterated RatingHoldLow
7/25/2018Wells Fargo & CompanyReiterated RatingHoldMedium
6/29/2018Cantor FitzgeraldSet TargetHold$41.00Medium
6/14/2018GuggenheimReiterated RatingBuy$59.00Medium
6/6/2018GuggenheimReiterated RatingBuy$59.00Medium
5/31/2018Wells Fargo & CompanySet TargetMarket Perform ➝ Hold$43.00 ➝ $41.00High
5/29/2018Bank of AmericaLower TargetNeutral ➝ Neutral$43.00 ➝ $42.00Medium
5/23/2018JPMorgan Chase & Co.Set TargetBuy$53.00Low
5/9/2018Cantor FitzgeraldSet TargetHold$41.00Low
4/23/2018Wells Fargo & CompanyReiterated RatingHoldLow
4/12/2018JPMorgan Chase & Co.Set TargetBuy$53.00Low
4/12/2018SVB LeerinkUpgradeMarket Perform ➝ Outperform$44.00Low
4/11/2018Cantor FitzgeraldSet TargetHold$41.00Medium
4/9/2018Morgan StanleySet TargetBuy$50.00High
4/3/2018Royal Bank of CanadaSet TargetHold$45.00Low
3/15/2018MizuhoBoost TargetBuy$45.00 ➝ $51.00Low
3/6/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$39.00 ➝ $50.00Medium
3/1/2018UBS GroupSet TargetBuy$54.00High
3/1/2018Cantor FitzgeraldSet TargetHold$41.00Medium
2/16/2018JPMorgan Chase & Co.Set TargetBuy$53.00Low
1/25/2018Susquehanna BancsharesReiterated RatingPositive ➝ Positive$47.00 ➝ $55.00Low
1/24/2018Deutsche Bank AktiengesellschaftSet TargetBuy$50.00Low
1/18/2018Wells Fargo & CompanySet TargetHold$33.00 ➝ $43.00Low
1/11/2018The Goldman Sachs GroupBoost TargetBuy$46.00 ➝ $52.00High
1/4/2018CitigroupReiterated RatingBuy ➝ Buy$48.00 ➝ $58.00High
1/2/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$44.00Low
12/26/2017Cantor FitzgeraldSet TargetHold$41.00Low
12/12/2017GuggenheimInitiated CoverageBuy ➝ Buy$59.00Low
12/4/2017UBS GroupSet TargetBuy$46.00Low
11/30/2017Cantor FitzgeraldSet TargetHold$34.00Medium
11/7/2017Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$32.00 ➝ $37.00N/A
10/31/2017Cantor FitzgeraldSet TargetHold$34.00N/A
10/24/2017MizuhoReiterated RatingBuy$37.00N/A
10/20/2017Royal Bank of CanadaSet TargetHold$32.00N/A
10/6/2017JPMorgan Chase & Co.Reiterated RatingOverweight$44.00 ➝ $48.00N/A
10/6/2017Morgan StanleyBoost TargetEqual Weight$36.00 ➝ $39.00N/A
10/5/2017UBS GroupReiterated RatingBuy$46.00N/A
10/5/2017Nomura InstinetReiterated RatingBuy$37.00N/A
10/5/2017CowenReiterated RatingMarket Perform$30.00 ➝ $36.00N/A
10/4/2017CitigroupSet TargetBuy$42.00N/A
10/4/2017MizuhoReiterated RatingBuy$37.00N/A
10/4/2017Wells Fargo & CompanySet TargetHold$30.00 ➝ $32.00N/A
10/4/2017Cantor FitzgeraldReiterated RatingHold$34.00High
10/4/2017BTIG ResearchBoost TargetBuy ➝ Buy$42.00 ➝ $45.00High
(Data available from 10/1/2017 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/5/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/4/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/4/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/3/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/2/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/1/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mylan logo
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $15.57
Low: $14.37
High: $15.86

52 Week Range

Now: N/A

Volume

14,100,488 shs

Average Volume

6,488,034 shs

Market Capitalization

$8.59 billion

P/E Ratio

29.92

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Mylan?

The following Wall Street research analysts have issued stock ratings on Mylan in the last year:
View the latest analyst ratings for MYL.

What is the current price target for Mylan?

0 Wall Street analysts have set twelve-month price targets for Mylan in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Mylan in the next year.
View the latest price targets for MYL.

What is the current consensus analyst rating for Mylan?

Mylan currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MYL.

What other companies compete with Mylan?

How do I contact Mylan's investor relations team?

Mylan's physical mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company's listed phone number is 724-514-1800 and its investor relations email address is [email protected] The official website for Mylan is www.mylan.com. Learn More about contacing Mylan investor relations.